Sign In
Buy CAR
$173.86
+1.48 (+0.86%)
At Close: Jun 03, 2026
Dublin, Oct. 21, 2024 (GLOBE NEWSWIRE) -- The "Spain Car Rental - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024-2029)" report has been added to ResearchAndMarkets.com's o
Poseida Therapeutics Announces Nomination of New CAR-T Development Candidate Under Collaboration with Roche
08:00am, Thursday, 17'th Oct 2024
Allogeneic, TSCM-rich dual CAR-T for the treatment of hematologic malignancies, including multiple myeloma Nomination triggers $15 million milestone payment to Poseida, extending cash runway into earl
Anixa Biosciences Announces Second Dose Administered to Patient in Ovarian Cancer CAR-T Clinical Trial
09:00am, Tuesday, 15'th Oct 2024
Patient showed clinical activity after initial treatment, with necrosis, inflammation, and T cell infiltration observed in tumor biopsy from the lowest dose SAN JOSE, Calif. , Oct. 15, 2024 /PRNewswir
New Strong Sell Stocks for October 15th
06:17am, Tuesday, 15'th Oct 2024
AMTB, CAR and BSET have been added to the Zacks Rank #24 (Strong Sell) List on October 15, 2024.
New Strong Sell Stocks for October 11th
04:35am, Friday, 11'th Oct 2024
ALLY, CAR and DNOW have been added to the Zacks Rank #5 (Strong Sell) List on October 11, 2024.
BENGALURU, India & HYDERABAD, India--(BUSINESS WIRE)-- #AurigeneOncology--Aurigene Oncology announces promising results of Phase 1 study for India's first trial for novel autologous CAR-T cell therapy
Maiden diamond drill program on CarLang B, C and E Zones intersected significant near surface mineralization CarLang C encountered highest grades to date on the CarLang Trend and covers an area approx
Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2
09:32am, Wednesday, 02'nd Oct 2024
Now dosing at dose expansion level of 450 million NXC-201 CAR+T cells. First cohort at 150 million CAR+T cells already successfully completed Each of these two doses have produced complete responses i
Anixa Biosciences Announces Submission of Protocol Amendment for CAR-T Trial
08:30am, Monday, 30'th Sep 2024
Amendment will allow a second dose of CAR-T therapy to suitable patients SAN JOSE, Calif. , Sept. 30, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechn
Data showed a 91% ORR with P-BCMA-ALLO1 in an optimized lymphodepletion arm, including a 100% ORR in BCMA-naïve patients, and an 86% ORR in those who had received at least one prior BCMA- and/or GPR
SAN JOSE, Calif. , Sept. 18, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today a
Verismo Therapeutics Awarded a ScaleReady™ G-Rex® Grant
07:00am, Tuesday, 17'th Sep 2024
PHILADELPHIA , Sept. 17, 2024 /PRNewswire/ -- Verismo Therapeutics, a clinical-stage CAR T company developing the novel KIR-CAR platform technology, today announced that it has been awarded a $150,00
Phio Pharmaceuticals Announces Presentation at the 9th Annual CAR-TCR Summit in Boston, MA
08:00am, Monday, 16'th Sep 2024
Phio's INTASYL self-delivering RNAi technology enhances cell potency and yield in Adoptive Cell Therapy Marlborough, Massachusetts--(Newsfile Corp. - September 16, 2024) - Phio Pharmaceuticals Corp. (
ST. PAUL, Minn. , Sept. 16, 2024 /PRNewswire/ -- ScaleReady and Bio-Techne Corporation (NASDAQ: TECH) today announced the launch of the G-Rex optimized ProPakTM GMP Cytokines, ideally tailored to high
Top 3 Industrials Stocks That May Rocket Higher In Q3
07:33am, Wednesday, 11'th Sep 2024
The most oversold stocks in the industrials sector presents an opportunity to buy into undervalued companies.
